Drugs / N-desmethylclozapine
N-desmethylclozapine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00628420 | Jan 2005 → Nov 2006 | schizophrenia | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT00490516 | Jun 2007 → Feb 2008 | schizophrenia | ACADIA Pharmaceuticals Inc. | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2008-06-16 | ACADIA Pharmaceuticals Inc. | Results ACADIA Pharmaceuticals Announces Results from ACP-104 Phase IIb Schizophrenia Trial acadia.com ↗
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) today announced results from its Phase IIb trial with ACP-104 for the treatment of schizophrenia. |
| 2008-04-04 | ACADIA Pharmaceuticals Inc. | Results ACADIA Pharmaceuticals to Present Preclinical Data on ACP-104, ACP-105 and Its Muscarinic Discovery Program at Experimental Biology 2008 Meeting acadia.com ↗
The data show that ACP-104 demonstrates pro-cognitive actions in an animal model by a muscarinic M1 receptor dependent mechanism. |
| 2007-11-02 | ACADIA Pharmaceuticals Inc. | Results ACADIA Pharmaceuticals to Present Preclinical Data on Its Advanced Schizophrenia Programs at the 37th Annual Meeting of the Society for Neuroscience acadia.com ↗
ACP-104: Demonstrates Positive Effects on Antipsychotic Activity and Cognition in Experimental Models |
| 2006-07-13 | ACADIA Pharmaceuticals Inc. | Results ACADIA Pharmaceuticals Announces Encouraging Results from Initial Clinical Trials with ACP-104 in Patients with Schizophrenia acadia.com ↗
The results of these studies demonstrated that ACP-104 is safe and well tolerated after repeated dosing of up to 600 mg per day, and that initial signals of antipsychotic effects were observed within the tolerated dose range of ACP-104. |
| 2005-11-10 | ACADIA Pharmaceuticals Inc. | Results ACADIA Pharmaceuticals Announces Initial Results From Ongoing Single-Dose Clinical Trial of ACP-104 in Schizophrenia Patients acadia.com ↗
ACP-104 was safe and well tolerated at all of the doses tested to date. |
| 2005-09-22 | ACADIA Pharmaceuticals Inc. | Results ACADIA Pharmaceuticals Study Identifies Molecular Properties of ACP-104 That Predict Unique Antipsychotic Activity acadia.com ↗
ACP-104, the major metabolite of clozapine, is a partial agonist that causes weak activation of dopamine D2 and D3 receptors, whereas clozapine and most other antipsychotic drugs block these receptors. |
| 2004-08-03 | ACADIA Pharmaceuticals Inc. | Results ACADIA Study Links ACP-104 (N-desmethylclozapine) to Improved Cognition in Schizophrenia Patients acadia.com ↗
The research, conducted by scientists at ACADIA and Vanderbilt University and published in 'Psychopharmacology' (July 16, 2004, e-pub), shows that ACP-104, the principal metabolite of clozapine, stimulates m1 muscarinic receptors in brain nerve cells that play an important role in cognition. |
All press releases naming this drug 9 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N-desmethylclozapine | “ACP-104 (N-desmethylclozapine)” NCT00628420 ↗ |
| Known as | ACP-104 | “ACP-104 (N-desmethylclozapine)” NCT00628420 ↗ |
| Known as | N-Demethylclozapine | ChEMBL registry synonym — accepted as the source's own label CHEMBL845 ↗ |
| Modality | Small molecule | — CHEMBL845 ↗ |
| Route | Oral | “after oral administration of single doses” NCT00628420 ↗ |